GSK's Votrient wins FDA approval

10/19/2009 | MarketWatch

GlaxoSmithKline's Votrient has gained FDA clearance to treat a form of kidney cancer called advanced renal cell carcinoma. The decision comes after an FDA panel unanimously voted to endorse the once-daily drug for approval.

View Full Article in:

MarketWatch